Aclaris Therapeutics Files 8-K on Operations, Officer Changes
Ticker: ACRS · Form: 8-K · Filed: Jan 19, 2024 · CIK: 1557746
| Field | Detail |
|---|---|
| Company | Aclaris Therapeutics, INC. (ACRS) |
| Form Type | 8-K |
| Filed Date | Jan 19, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, officer-changes, compensatory-arrangements
TL;DR
**Aclaris Therapeutics just dropped an 8-K hinting at big financial and leadership news.**
AI Summary
Aclaris Therapeutics, Inc. filed an 8-K on January 19, 2024, reporting events that occurred on January 15, 2024. This filing indicates that the company is reporting on its results of operations and financial condition, as well as changes in its directors or officers and their compensatory arrangements. For investors, this matters because it signals that significant financial and leadership updates are forthcoming or have just occurred, which could impact the company's strategic direction and financial performance.
Why It Matters
This filing signals upcoming or recent changes in Aclaris Therapeutics' financial health and leadership, which are critical factors for evaluating the company's future prospects and stock value.
Risk Assessment
Risk Level: medium — Changes in financial condition and officer compensation can introduce uncertainty, making the risk level medium until specific details are disclosed.
Analyst Insight
A smart investor would await the detailed disclosures regarding the 'Results of Operations and Financial Condition' and 'Compensatory Arrangements of Certain Officers' to understand the full impact on Aclaris Therapeutics' financial health and leadership stability before making investment decisions.
Key Players & Entities
- Aclaris Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 15, 2024 (date) — date of earliest event reported
- January 19, 2024 (date) — date the 8-K was filed
- 001-37581 (number) — Commission File Number for Aclaris Therapeutics
- ACRS (company) — trading symbol for Aclaris Therapeutics
FAQ
What specific items did Aclaris Therapeutics, Inc. report in this 8-K filing?
Aclaris Therapeutics, Inc. reported on 'Results of Operations and Financial Condition' and 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' as per the 'ITEM INFORMATION' section of the filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 15, 2024, as stated in the 'Date of Report (Date of earliest event reported): January 15, 2024' section.
What is the trading symbol and the exchange where Aclaris Therapeutics, Inc. common stock is registered?
Aclaris Therapeutics, Inc.'s common stock trades under the symbol ACRS and is registered on The Nasdaq Stock Exchange, as indicated under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the business address of Aclaris Therapeutics, Inc.?
The business address of Aclaris Therapeutics, Inc. is 701 Lee Road, Suite 103, Wayne, PA 19087, as listed in the 'BUSINESS ADDRESS' section of the filing.
What is the purpose of an 8-K filing for Aclaris Therapeutics, Inc. in this context?
An 8-K filing is a 'CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934' used by Aclaris Therapeutics, Inc. to announce material events that shareholders should know about, such as changes in financial condition or leadership, as reported on January 15, 2024.
Filing Stats: 874 words · 3 min read · ~3 pages · Grade level 11.7 · Accepted 2024-01-19 07:30:10
Key Financial Figures
- $0.00001 — ange on which Registered Common Stock, $0.00001 par value ACRS The Nasdaq Stock Mar
Filing Documents
- acrs-20240115x8k.htm (8-K) — 43KB
- acrs-20240115xex99d1.htm (EX-99.1) — 14KB
- acrs-20240115xex99d1001.jpg (GRAPHIC) — 13KB
- 0001558370-24-000373.txt ( ) — 199KB
- acrs-20240115.xsd (EX-101.SCH) — 3KB
- acrs-20240115_lab.xml (EX-101.LAB) — 16KB
- acrs-20240115_pre.xml (EX-101.PRE) — 10KB
- acrs-20240115x8k_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 16, 2024, Aclaris Therapeutics, Inc. (the " Company ") issued a press release announcing, among other things, its preliminary unaudited aggregate cash, cash equivalents and marketable securities as of December 31, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) Departure of Douglas Manion as Chief Executive Officer and President and Director On January 15, 2024, the Company and Douglas Manion mutually agreed that Dr. Manion will step down as the Company's Chief Executive Officer and President and resign from the Board of Directors (the " Board "), effective January 16, 2024. Dr. Manion's resignation from the Board was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. (c) Appointment of Neal Walker as Interim Chief Executive Officer and President In connection with the departure of Dr. Manion, on January 15, 2024, the Board appointed Neal Walker as the Company's Interim Chief Executive Officer and President, effective January 17, 2024. Dr. Walker will continue to serve as
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated January 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ACLARIS THERAPEUTICS, INC. By: /s/ Kevin Balthaser Date: January 19, 2024 Kevin Balthaser Chief Financial Officer 4